Mouse Models of Autoimmune Uveitis

Author(s): Izabela P. Klaska, John V. Forrester

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 18 , 2015

Become EABM
Become Reviewer
Call for Editor

Abstract:

Uveitis is a sight threatening intraocular inflammation accounting for approximately 10% of blindness worldwide. On the basis of aetiology, disease can be classified as infectious or non-infectious; and by anatomical localization of inflammation as anterior, posterior and panuveitis. Non-infectious uveitis is believed to be autoimmune in nature with Th1 and Th17 cells being identified as the prominent effector cell types. Numerous animal models of autoimmune uveitis were developed contributing to our understanding of this inflammatory condition. The classical peptide-induced experimental autoimmune uveoretinitis (EAU) model resembles human posterior uveitis due to the recurrent/relapsing nature of the disease; while the intraocular inflammation triggered by administration of bacterial lipopolisaccharide (endotoxin-induced uveitis, EIU) mimics closely anterior uveitis. The clinical need for novel, more targeted forms of anti-inflammatory therapy has emerged as currently available therapeutic strategies are associated with a number of adverse effects and intolerance in patients. This review summarises knowledge about existing mouse models of uveitis, discusses mechanisms driving intraocular inflammation and describes possible customised translational treatment strategies that can be potentially used in the clinic to prevent blindness in patients.

Keywords: Uveitis, autoimmunity, inflammation, uveitogenic antigens, animal models, Th1, Th17.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 18
Year: 2015
Published on: 30 April, 2015
Page: [2453 - 2467]
Pages: 15
DOI: 10.2174/1381612821666150316122928
Price: $65

Article Metrics

PDF: 101
HTML: 10